Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $129
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Jayson Bedford has maintained an 'Outperform' rating on Abbott Laboratories and raised the price target from $122 to $129.
October 14, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reaffirmed its 'Outperform' rating for Abbott Laboratories and increased the price target to $129, indicating confidence in the company's future performance.
The increase in price target from $122 to $129 by Raymond James suggests a positive outlook on Abbott Laboratories' future performance. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100